<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2558">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04459702</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-043</org_study_id>
    <nct_id>NCT04459702</nct_id>
  </id_info>
  <brief_title>A Study of Combination Therapies to Treat COVID-19 Infection</brief_title>
  <official_title>A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Big Corona Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine whether dual or quadruple therapy is more effective in treating
      COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients will be administered either dual or quadruple therapy and have PCR
      tests run daily to determine efficacy as indicated by time to non-infectivity
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores</measure>
    <time_frame>6 months</time_frame>
    <description>Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Treatment by Time to Non-Infectivity</measure>
    <time_frame>10 days</time_frame>
    <description>Time to non-infectivity as measured by PCR testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores</measure>
    <time_frame>6 months</time_frame>
    <description>Patient symptoms will be recorded using the NEWS system, which rates patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.</measure>
    <time_frame>6 months</time_frame>
    <description>Patient symptoms will be recorded using the NEWS system, which rates patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Complete Blood Count</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in blood parameters measured in a Complete Blood Count (CBC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Complete Blood Count</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in blood parameters measured in a Complete Metabolic Panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel -Albumin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum albumin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum albumin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum albumin/globulin ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum albumin/globulin ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum alkaline phosphatase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum alkaline phosphatase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - AST</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum AST levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - AST</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum AST levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum ALT levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel ALT</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum ALT levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum BUN/Creatinine Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum BUN/Creatinine Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum Blood Urea Nitrogen levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - BUN</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum Blood Urea Nitrogen levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Calcium</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum calcium levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum calcium levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum carbon dioxide levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum carbon dioxide levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Chloride</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum chloride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum chloride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum creatinine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum creatinine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Globulin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum globulin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum globulin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in blood glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Glucose</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in blood glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Potassium</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in blood potassium levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in blood potassium levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum total bilirubin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum total bilirubin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum total protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in serum total protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Dual Therapy as Measured by Treatment Related SAE</measure>
    <time_frame>6 months</time_frame>
    <description>Presence or absence of treatment related serious adverse events Grade III or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Quadruple Therapy as Measured by Treatment Related SAE</measure>
    <time_frame>6 months</time_frame>
    <description>Presence or absence of treatment related serious adverse events Grade III or higher</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID</condition>
  <condition>COVID-19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Coronavirus Infection</condition>
  <condition>Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere</condition>
  <condition>Coronavirus-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>SARS Pneumonia</condition>
  <arm_group>
    <arm_group_label>Dual Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual Therapy utilizing hydroxychloroquine and azithromycin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadruple therapy utilizing hydroxychloroquine, lopinavir, ritonavir, and azithromycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxychloroquine</intervention_name>
    <description>Treatment with the drug hydroxychloroquine</description>
    <arm_group_label>Dual Therapy</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Treatment with the drug azithromycin</description>
    <arm_group_label>Dual Therapy</arm_group_label>
    <arm_group_label>Quadruple Therapy</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Treatment with the drug ritonavir</description>
    <arm_group_label>Quadruple Therapy</arm_group_label>
    <other_name>norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir</intervention_name>
    <description>Treatment with the drug lopinavir</description>
    <arm_group_label>Quadruple Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent, demonstrating that the subject understands the procedures
             required for the study and the purpose of the study

          2. Healthy, ambulant male or female subjects 18 years of age to 65 years of age

          3. Positive test for COVID-19 by RT-PCR at screening

          4. Subjects must agree to practice at least one highly effective method of birth control
             for the duration of the study. This includes condoms with spermicide, oral birth
             control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects
             not of reproductive potential will be exempt (e.g. post-menopausal, surgically
             sterilized)

          5. Subjects must agree they will do their best to attend the treatment facility daily for
             10 days

        Exclusion Criteria:

          1. Refusal to sign informed consent form

          2. Negative test for COVID-19 by RT-PCR at screening

          3. Severe disease symptomatically including pneumonia, respiratory distress, tachypnea,
             shortness of breath, temperature &gt; 38 degrees; pleuritic pain, or frequent cough.

          4. Known drug allergy to any of the investigational medications

          5. Currently taking medication with known drug interactions with investigational
             medications (listed in appendix)

          6. Prescription or other antiviral medications

          7. Any comorbidities which constitute health risk for the subject

          8. Pregnant or lactating females;

          9. weight &lt; 110lb;

         10. porphyria

         11. established retinal disease

         12. Inability to attend daily for 10 days

         13. Any contraindications for treatment with hydroxychloroquine

               1. Hypoglycemia

               2. Known G6PD deficiency

               3. Porphyria

               4. Anemia

               5. Neutropenia

               6. Alcoholism

               7. Myasthenia gravis

               8. Skeletal muscle disorders

               9. Maculopathy

              10. Changes in visual field

              11. Liver disease

              12. Psoriasis

              13. History of QT &gt;500msec

              14. History of torsades de pointes

         14. Anemia from pyruvate kinase and G6PD deficiencies

         15. Abnormal EKG with QT prolongation acquired or from birth

         16. History of jaundice or high fevers prior to developing COVID-19

         17. Treatment with any of the medications listed in Appendix II

         18. Treatment with any anti-epileptic medication

         19. Treatment with any other drug not listed that affects the QT interval
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Borody, MD, PhD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Big Corona Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>805-339-0549</phone>
    <email>drsabinehazan@progenabiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>805-339-0549</phone>
    <email>jordan@progenabiome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>July 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 4, 2020</last_update_submitted>
  <last_update_submitted_qc>July 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

